Targeting Drug Resistance and Tumor Heterogeneity
Date: Tuesday April 18, 2017
Check-in and Breakfast: 8 am to 8:30 am
Time: 8:30 am to 5:00 pm
Location: Hilton Garden Inn • 1 Circle Road, Stony Brook, NY
***Breakfast and lunch are included at this event***
The full agenda will be posted on March 15, 2017.
At the 2017 Symposium, we are looking forward to our local Stony Brook expert presentations in cancer drug development and efforts to tackle drug resistance and tumor heterogeneity. We are also pleased to announce that the following leading experts in their fields will be joining us and sharing their insights and progress in cancer drug development.
Jeffrey M. Rosen, PhD, is the Charles C. Bell Professor of Molecular and Cellular Biology at Baylor College of Medicine. Dr. Rosen is recognized for his work on elucidating the mechanisms regulating normal mammary gland development, and to determine how these regulatory mechanisms have deviated in breast cancer for therapeutic discovery. He is an expert in animal models of breast cancer and their use in biology and drug discovery and will present “From Bench to Cageside: Therapeutic insights from Preclinical GEM models”
https://www.bcm.edu/research/labs/jeffrey-rosen
Michael J. Eck, MD, PhD, is Professor, Biological Chemistry and Molecular Pharmacology, Harvard Medical School and Professor, Cancer Biology, Dana-Farber Cancer Institute. He is recognized for his work in understanding how cancer-causing mutations lead to loss of normal kinase regulation, and in using structural approaches to develop new anticancer drugs. Active areas of investigation include: (1) the structure and regulation of Jak-family kinases and their interactions with cytokine receptors, (2) lung cancer-derived mutations in the epidermal growth factor receptor (EGFR), (3) the structural biology of focal adhesion kinase (FAK), and (4) formin proteins and their role in assembling the actin cytoskeleton. http://red.dfci.harvard.edu/ He will speak on his experience overcoming treatment resistance that arises from target mutation: “Targeting drug resistant EGFR with a mutant-selective allosteric inhibitor”.
Patricia M. LoRusso, DO, is the Associate Director of Innovative Medicine and Professor of Medicine Yale Cancer Center. She is an expert on drug development through clinical trials. She is recognized as a ‘transformational’ for her leadership role in cancer clinical trials. Dr. LoRusso has served as co-chair of the National Cancer Institute (NCI) Cancer Therapy Evaluation Program Investigational Drug Steering Committee. She also served on the scientific committee of the American Association for Cancer Research, the education and scientific committees of the ASCO, numerous peer-reviewed study sections, and NCI committees. She states, “My primary mission is to make a difference in human lives, and one of the ways to do this is by bringing the very latest therapies to patients through clinical trials.” Dr. LoRusso will present on her clinical trial experience. https://medicine.yale.edu/cancer/patient/people/patricia_lorusso.profile
REGISTRATION WILL CLOSE ON TUESDAY, APRIL 11, AT 3PM.
If you would like to be considered for late registration, please email Lauren Cutaia at lauren.cutaia@stonybrookmedicine.edu